These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25597633)

  • 1. Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.
    Anbalagan M; Rowan BG
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():264-72. PubMed ID: 25597633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable inhibition of specific estrogen receptor α (ERα) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells.
    Huderson BP; Duplessis TT; Williams CC; Seger HC; Marsden CG; Pouey KJ; Hill SM; Rowan BG
    Endocrinology; 2012 Sep; 153(9):4144-59. PubMed ID: 22733972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
    Al-Dhaheri MH; Rowan BG
    Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of Estrogen Receptor α at serine 118 directs recruitment of promoter complexes and gene-specific transcription.
    Duplessis TT; Williams CC; Hill SM; Rowan BG
    Endocrinology; 2011 Jun; 152(6):2517-26. PubMed ID: 21505052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.
    Sisci D; Maris P; Cesario MG; Anselmo W; Coroniti R; Trombino GE; Romeo F; Ferraro A; Lanzino M; Aquila S; Maggiolini M; Mauro L; Morelli C; Andò S
    Cell Cycle; 2013 Nov; 12(21):3405-20. PubMed ID: 24047697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCAS2 Enhances Carcinogenic Effects of Estrogen Receptor Alpha in Breast Cancer Cells.
    Salmerón-Hernández Á; Noriega-Reyes MY; Jordan A; Baranda-Avila N; Langley E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.
    Rajbhandari P; Finn G; Solodin NM; Singarapu KK; Sahu SC; Markley JL; Kadunc KJ; Ellison-Zelski SJ; Kariagina A; Haslam SZ; Lu KP; Alarid ET
    Mol Cell Biol; 2012 Jan; 32(2):445-57. PubMed ID: 22064478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-α and ERK2 that controls breast cancer proliferation and invasiveness properties.
    Kim K; Madak-Erdogan Z; Ventrella R; Katzenellenbogen BS
    Horm Cancer; 2013 Apr; 4(2):78-91. PubMed ID: 23250869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.
    Droog M; Nevedomskaya E; Dackus GM; Fles R; Kim Y; Hollema H; Mourits MJ; Nederlof PM; van Boven HH; Linn SC; van Leeuwen FE; Wessels LF; Zwart W
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1316-E1325. PubMed ID: 28167798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
    Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
    J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17β-estradiol enhances α(5) integrin subunit gene expression through ERα-Sp1 interaction and reduces cell motility and invasion of ERα-positive breast cancer cells.
    Sisci D; Middea E; Morelli C; Lanzino M; Aquila S; Rizza P; Catalano S; Casaburi I; Maggiolini M; Andò S
    Breast Cancer Res Treat; 2010 Nov; 124(1):63-77. PubMed ID: 20052536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
    Ring KL; Yates MS; Schmandt R; Onstad M; Zhang Q; Celestino J; Kwan SY; Lu KH
    Int J Gynecol Cancer; 2017 Jun; 27(5):854-862. PubMed ID: 28498246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells.
    Laganière J; Deblois G; Giguère V
    Mol Endocrinol; 2005 Jun; 19(6):1584-92. PubMed ID: 15831516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
    Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
    J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor α function in breast cancer via the Wnt pathway.
    Lim SK; Orhant-Prioux M; Toy W; Tan KY; Lim YP
    FASEB J; 2011 Sep; 25(9):3004-18. PubMed ID: 21642474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.